Slingshot members are tracking this event:

Phase 2 open-label trial data of FG-3019 for Pancreatic cancer to be presented at 2016 Gastrointestinal Cancers Symposium of ASCO GI in January 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details FibroGen is evaluating the potential of FG-3019 to convert inoperable pancreatic cancer to operable cancer in a randomized Phase 2 open-label study.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 22, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Fg-3019, Pancreatic Cancer, Gastrointestinal Cancers Symposium